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ORIGINAL ARTICLE
With advances in surgical techniques and peri-
operative care, hepatic resection for hepatocel-
lular carcinoma (HCC) can be performed with a
low hospital mortality rate, even in patients with
chronic liver disease.1,2 The results of hepatic re-
section for early-stage HCC3 were favorable, with
5-year survival rates ranging from 40% to 70%.4–6
For patients with large HCC, defined as HCC 
> 5 cm,7 or even > 10 cm in diameter,8 several au-
thors, on the basis of results from their individ-
ual centers, have advocated hepatic resection.
Nevertheless, the role of surgical resection for
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multinodular HCC (MNHCC) is less well-defined.
The presence of multiple tumors has been shown
to be one of the most significant independent
factors to influence cumulative survival rates in
patients with HCC who are undergoing hepatic
resection.9–12 As a result of multicentric carcino-
genesis or intrahepatic metastasis, MNHCC may
benefit from palliation with local ablative treat-
ment or chemoembolization rather than from
hepatic resection,3 but there are few clinical stud-
ies to validate this recommendation.
Although liver transplantation provides an al-
ternative curative treatment option for MNHCC
with size ≤ 5 cm in diameter and tumor number <
3,13,14 its application is limited by the shortage 
of organs in both Eastern and Western countries.
Therefore, hepatic resection is still the mainstay
of curative treatment for MNHCC, and surgical
resection should be considered for all noncir-
rhotic patients or those with well-compensated
Child-Pugh class A cirrhosis, without evidence of
portal hypertension once they are free from ex-
trahepatic spread.15 The objective of the present
study was to evaluate the long-term survival of
patients with hepatic resection for MNHCC. We
also examined nonsurgical multidisciplinary ther-
apy during the same period for comparison, in
the hope that it may help us to select a subgroup
of patients with MNHCC who will benefit most
from aggressive surgical intervention.
Patients and Methods
We reviewed the charts of 599 patients who had
undergone hepatic resection for HCC in the
Department of Surgery, Veterans General Hospital,
Kaohsiung, Taiwan, during the 15-year period be-
tween October 1990 and June 2006. There were
16 surgical deaths (2.7%). Forty-nine patients were
excluded from the study for loss to follow-up
within 12 months after operation. In the remain-
ing 537 patients, 425 had a single tumor, while
112 had MNHCC.
The tumors were evaluated preoperatively by
ultrasonography, computed tomography (CT),
magnetic resonance imaging (MRI) and hepatic
arteriography, if indicated. In all patients, serum
levels of α-fetoprotein (AFP), hepatitis B surface
antigen (HBsAg) and anti-hepatitis C virus anti-
body (anti-HCVAb) were determined, and con-
ventional liver function tests and the indocyanine
green (ICG) clearance test were performed.
Couinaud’s liver segmentation was used to ex-
press tumor location and extent of hepatectomy.16
Intraoperative ultrasonography was performed
routinely to detect tumor nodules in the con-
tralateral lobe, invasion of the tumor into the
major blood vessels, and to mark the line of
parenchymal transection on the liver surface to
obtain an optimal tumor-free margin.
The classification of MNHCC was as follows:
type A, multiple nodules that were close to each
other and involved one or two adjoining seg-
ments; type B, large tumor with satellite nodules
that involved three or more segments; type C,
three or fewer nodules that were scattered in re-
mote segments; and type D, more than three sep-
arate tumors (Figure 1). Type A tumors could be
removed in one block. Type B–D tumors could be
removed in one block with lobectomy or extended
hepatectomy, if the tumors were confined to one
side of the liver; otherwise multiple-site resection
was employed. To determine the prognostic factors
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Figure 1. Classification of multinodular hepatocellular car-
cinoma. Type A tumors can be removed in one block. Type
B–D tumors can be removed in one block with lobectomy
or extended hepatectomy if confined to one side of the
liver, otherwise multiple-site resection is required.
of hepatectomy for MNHCC, the clinicopathologic
and biological variables of the 112 patients were
analyzed. Those with tumors that were removed
in one block and those that needed multiple-site
hepatic resection were compared.
To investigate the efficacy of hepatectomy for
MNHCC, we also looked at the database of 874
patients who had undergone nonsurgical multidis-
ciplinary therapy for HCC during the same period.
The detection of HCC was initially carried out
with abdominal ultrasonography and spiral CT,
MRI with contrast enhancement, or angiography
with lipiodol injection. Follow-up CT was used
for accurate diagnosis of MNHCC. There were
319 (36.5%) patients, of whom 178 underwent
image-guided percutaneous needle biopsy for
pathologic tissue investigation. To compare liver
function, we enrolled 110 patients who had serum
albumin > 3.5 g/dL and total bilirubin < 2.0 mg/
dL, who had been followed for at least 12 months
after treatment. The choice of treatment modality
was as follows. Generally, percutaneous acetic acid
injection (PAI) or radiofrequency ablation (RFA)
was used for ≤ 3 liver tumors and tumor size <
3 cm. Transcatheter arterial embolization (TAE)
was used for tumors with well-enhanced contrast
in imaging studies. Hepatic arterial infusion (HAI)
was used for those with > 4 tumors and those with
poor response to TAE. The methods of PAI, TAE
and HAI were as described in previous studies.17
Post-treatment follow-up was done with conven-
tional liver function tests, serum AFP level, and
abdominal ultrasonography at intervals of 2–3
months. CT was performed every 6 months, and
ultrasonography in those who had suspected le-
sions. Chest roentgenography, whole-body bone
scan or other imaging studies were undertaken if
indicated, to detect possible recurrence. For those
with liver recurrence, further hepatectomy was con-
sidered for the surgical group if liver functional
reserve was adequate. Otherwise, the treatments
were as described for nonsurgical multidisciplinary
treatment.
The variable data were expressed as mean ±
standard deviation. Mean values were compared
by unpaired Student’s t test, and the χ2 test was
used to compare percentages. Survival was ana-
lyzed by the Kaplan–Meier method, and survival
curves were compared by the log-rank test. A value
of p < 0.05 was considered statistically significant.
The significance of the prognostic value of the
variables was estimated with Cox’s multivariate
proportional hazards model.
Results
Comparison of surgical results between 
single HCC and MNHCC
The surgical mortality rates for single HCC and
MNHCC were similar (2.2 vs. 2.7%). The overall
1-, 3- and 5-year survival rates for patients with
single HCC and MNHCC were 88.0%, 69.2%
and 58.4%, and 86.1%, 55.5% and 29.9%, re-
spectively (p < 0.001).
Clinicopathologic analysis of patients
undergoing hepatectomy for MNHCC
The clinical features and types of hepatic resec-
tion performed are summarized in Table 1. Of the
112 patients, recurrence of HCC was detected in
93 (88.8%), with a median disease-free survival
period of 11 months (range, 2–147 months). Extra-
hepatic recurrence occurred in 27 patients (24.3%),
including lung (12 patients), bone (6 patients),
lymph nodes (6 patients), intra-abdominal seed-
ing (5 patients), adrenal gland (3 patients), and
brain (2 patients). The 1-, 3- and 5-year disease-
free survival rates were 45.7%, 29.2% and 18.4%,
respectively. The results of hepatectomy are shown
in Table 2. The overall cumulative survival rates
at 1, 3 and 5 years were 86.1%, 55.5% and 29.9%,
respectively (Figure 2). The median overall survival
period was 47.0 months.
Treatment for recurrence
Of the 93 patients with recurrence, 13 underwent
second hepatectomy and one a third hepatec-
tomy. Twenty-five patients underwent local abla-
tive therapy, including 44 sessions of PAI for 13
patients, and 25 sessions of RFA for 16 patients.
Fifty-two patients underwent a total of 157 TAE
B.W. Wang, et al
618 J Formos Med Assoc | 2008 • Vol 107 • No 8
procedures, with an average of three procedures
per patient (1–12 procedures). Twenty-six patients
underwent a total of 65 courses of HAI. Twenty-
one patients did not receive treatment of any
kind. Seven patients were free from disease after
multidisciplinary therapy for recurrence.
Prognostic factors for survival
Table 3 contains the univariate analysis of survival
for 112 patients after hepatectomy for MNHCC,
according to various prognostic parameters.
Among the host factors, age, gender, HBsAg sta-
tus, and anti-HCVAb status did not have a signif-
icant influence on survival. Patients with liver
cirrhosis or with elevated liver function enzymes
(alanine aminotransferase and aspartate amino-
transferase) did not have a worse outcome. Pres-
ence of satellite nodules did not have a major
prognostic influence. Blood transfusion during
hepatectomy or anatomical hepatic resection did
not have an influence on outcome. High-grade
tumor differentiation, macroscopic vascular inva-
sion, resection margin < 10 mm, and bilobar in-
volvement adversely affected survival, but not
significantly. In the present study, significant un-
favorable prognostic factors included AFP level >
400 ng/mL, total tumor size > 5 cm, largest tumor
size>5 cm, total tumor number >3, microvascular
Hepatectomy for multinodular HCC
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Table 1. Clinical features of 112 patients with
multinodular hepatocellular carcinoma
(number of tumors ≥ 2) who underwent
hepatic resection
Age (yr) 59.0 ± 13.0
Male:female 98:14 (7:1)
Positive HBsAg 69/112 (61.6%)
Positive anti-HCVAb 35/99 (35.4%)
AFP < 20 ng/mL 53/112 (47.3%)
Largest tumor size (cm)
< 5 54 (48.2%)
5–10 34 (30.4%)
> 10 24 (21.4%)
Type of multinodularity
A 21 (18.8%)
B 48 (42.9%)
C 29 (25.9%)
D 14 (12.5%)
Hepatectomy type
Resection in one block 69 (61.6%)
One segment 17 (15.2%)
Two segments 13 (11.6%)
Three segments 3 (2.7%)
Right lobectomy 13 (11.6%)
Extended right lobectomy 1 (0.9%)
Left lateral segmentectomy 9 (8.0%)
Left lobectomy 10 (8.9%)
Extended left lobectomy 3 (2.7%)
Multiple-site resection 43 (38.2%)
Two separate (sub)segments 19 (17.0%)
Two segments + one wedge 11 (9.8%)
Right lobectomy + one wedge 5 (4.5%)
Left lobectomy + one wedge 1 (0.9%)
Multiple wedges (> 3) 7 (6.3%)
HBsAg = hepatitis B surface antigen; HCVAb = hepatitis C virus
antibody; AFP = a-fetoprotein.
Table 2. Results of 112 patients who underwent
hepatectomy for multinodular
hepatocellular carcinoma
Patients (n) Survival duration (mo)
NED 17 15–147
AWD 4 15–76
DOO 2 16–84
LOF 7 27–114
DOD 82 3–132
NED = no evidence of disease; AWD = alive with disease; DOO =
died of other disease; LOF = lost to follow-up; DOD = died of 
disease.
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Figure 2. Disease-free () and overall () survival rates
for 112 patients with multinodular hepatocellular carcinoma
treated with hepatectomy.
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Table 3. Univariate analysis of variables related to overall survival of patients who underwent hepatectomy
for multinodular hepatocellular carcinoma
Overall survival (%)
n 3 yr 5 yr
p
Age (yr) 0.860
< 65 68 47 30
≥ 65 44 50 18
Gender 0.351
Male 98 48 25
Female 14 55 39
Diabetes mellitus 0.228
Presence 22 34 14
Absence 90 52 30
HBsAg 0.956
Positive 68 45 28
Negative 44 54 25
Anti-HCVAb 0.138
Positive 36 61 38
Negative 76 43 22
Liver cirrhosis 0.350
Presence 62 43 22
Absence 50 57 35
ICG-R15 (%) 0.899
> 10 52 48 19
≤ 10 45 43 27
Albumin (g/dL) 0.659
≤ 3.6 34 49 30
> 3.6 78 48 26
Total bilirubin (mg/dL) 0.592
≥ 1.0 32 57 26
< 1.0 80 45 28
ALT (U/L) 0.508
> 50 61 45 22
≤ 50 51 53 33
AST (U/L) 0.510
> 90 24 45 19
≤ 90 88 50 29
AFP (ng/mL) 0.043*
≥ 400 36 32 24
< 400 76 56 29
Platelet count (× 103/mm2) 0.145
≥ 150 61 42 22
< 150 50 56 32
(Contd.)
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Table 3. Continued
Overall survival (%)
n 3 yr 5 yr
p
Blood transfusion 0.232
Presence 65 42 25
Absence 46 55 28
Resection margin (mm) 0.097
≥ 10 59 46 13
< 10 53 51 36
Total tumor size (cm) 0.010*
> 5 79 38 22
≤ 5 33 74 38
Largest tumor size (cm) 0.006*
> 5 58 32 22
≤ 5 54 65 33
Type of multinodularity 0.020
A 48 64 36
B 21 24 19
C 29 40 12
D 14 51 33
Tumor number 0.024*
> 3 48 37 23
≤ 3 64 57 30
Bilobar involvement 0.058
Presence 32 31 20
Absence 80 55 30
Satellite nodules 0.988
Presence 53 42 34
Absence 59 55 22
Great vessel invasion 0.065
Presence 18 32 24
Absence 93 52 27
Microvascular invasion 0.006*
Presence 56 35 24
Absence 56 62 31
Tumor grade 0.071
III or IV 44 34 23
I or II 68 56 30
Anatomical resection 0.645
Yes 36 50 36
No 76 48 24
Resection in one block 0.012*
Yes 68 58 35
No (multiple-site resection) 44 35 16
*p < 0.05. HBsAg = hepatitis B surface antigen; HCVAb = hepatitis C virus antibody; ICG-R15 = indocyanine green 15-minute retention
rate; ALT = alanine aminotransferase; AST = aspartate aminotransferase; AFP = a-fetoprotein.
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invasion and multiple-site resection. The type 
of multinodularity was also found to influence
prognosis. Those with nodules that were close to
each other and that involved one or two adjoin-
ing segments (type A) had better survival than
the other three types. By multivariate analysis,
only multiple-site resection was an independent
unfavorable prognostic factor that affected long-
term survival (Table 4).
Comparison between hepatectomy and
nonsurgical treatment
The overall cumulative survival rates for the 
110 patients with serum albumin level ≥ 3.5 g/dL
and total bilirubin level < 2 mg/dL in the nonsur-
gical group at 1, 3 and 5 years were 68.2%, 24.7%
and 7.9%, respectively. The median overall sur-
vival period was 20 months, which was signifi-
cantly shorter than that in the surgical group (47
months).
We further investigated the efficacy of hepa-
tectomy for those with tumor number ≤ 3 and
largest tumor size ≤ 5 cm. There were 47 patients
enrolled in the nonsurgical group and 38 in the
surgical group. The clinical features are summa-
rized in Table 5. There was no significant difference
in the rate of hepatitis B or C infection. The num-
ber of patients with elevated serum AFP, alanine
aminotransferase and aspartate aminotransferase
was not significantly different between the two
groups. The proportion of type A multinodular-
ity and percentage with bilobar involvement in
the two groups were comparable. Among the 47
patients in the nonsurgical group, 44 underwent
188 sessions of TAE, 27 underwent 91 sessions of
PAI, six underwent 11 sessions of RFA, and six
underwent eight courses of HAI. Of the 38 pa-
tients in the hepatectomy group, four had no 
recurrence. Of the remaining 34 patients with re-
currence, 22 underwent 85 sessions of TAE, six
underwent 28 sessions of PAI, six underwent
eight sessions of RFA, and seven underwent 13
courses of HAI.
There were six patients with extrahepatic metas-
tasis in the nonsurgical group and five with ex-
trahepatic recurrence in the hepatectomy group.
Among the nonsurgical patients, 10 were still alive
(3 had no evidence of disease and 7 were alive
with disease), three patients died of complications
associated with liver cirrhosis (gastrointestinal
bleeding, spontaneous bacterial peritonitis and
hypoglycemia, respectively), and the remaining
35 patients died of the disease. Among the hepa-
tectomy group, seven had no evidence of disease
and two were alive with disease. The overall cumu-
lative 1-, 3- and 5-year survival rates in the hepa-
tectomy group were 94.6%, 66.8% and 26.2%,
respectively, with a median survival of 49 months.
The result was significantly better than in the
nonsurgical group, in which the cumulative 1-,
3- and 5-year survival rates were 87.5%, 42.1%
and 22.6%, respectively, with a median survival
of 30 months (p = 0.0327) (Figure 3). However,
for those with tumor number ≤ 3 and tumor size
≤ 5 cm, 22 patients who underwent multiple-site
hepatic resection showed no survival advantage
against the 47 patients who received nonsurgical
multidisciplinary therapy. In contrast, the group
Table 4. Multivariate analysis of independent variables related to overall survival of patients with
multinodular hepatocellular carcinoma who underwent hepatectomy
Hazard ratio 95% CI p
Multiple resection 2.204 1.277–3.803 0.005*
Largest tumor size > 5 cm 1.776 0.972–3.243 0.062
Microvascular invasion 1.634 0.971–2.748 0.064
Tumor number > 3 1.261 0.781–2.037 0.343
AFP > 400 ng/mL 1.176 0.680–2.035 0.562
Non-A type tumor 1.161 0.663–2.034 0.601
Total tumor size > 5 cm 1.067 0.528–2.154 0.857
*p < 0.05. CI = confidence interval; AFP = a-fetoprotein.
of 16 patients who underwent one-block resec-
tion for MNHCC had significantly better survival
(p = 0.0016) (Figure 4).
Discussion
The prognosis of HCC is generally poor. Partial
hepatectomy remains the best hope for a cure but
is suitable for only 9–27% of patients.16 One of
the major causes of such a low resectability rate
is the presence of significant background cirrho-
sis. The other possible cause is the high incidence
of tumor multiplicity, because patients with mul-
tiple tumors have a poorer outcome compared
with those with a solitary tumor.9–11 This has also
been demonstrated in the present study, which
shows that survival of patients with MNHCC 
Hepatectomy for multinodular HCC
J Formos Med Assoc | 2008 • Vol 107 • No 8 623
Table 5. Comparison between nonsurgical and hepatectomy groups with tumor number ≤ 3, largest tumor
size ≤ 5 cm, serum albumin > 3.0 g/dL and serum total bilirubin < 2.0 mg/dL
Nonsurgical (n = 47) Hepatectomy (n = 38) p
Age (yr) 65.3 ± 11.6 61.9 ± 11.2 NS
Gender (M/F) 36/12 30/7 NS
Platelet count < 150 × 103/mm3 34 23 NS
AST > 90 U/L 13 8 NS
ALT > 50 U/L 31 22 NS
HBsAg 18 19 NS
HCVAb 30 15 NS
AFP < 20 (ng/mL) 16 20 NS
Largest tumor size ≤ 2 cm 14 9 NS
Bilobar tumor involvement 21 12 NS
Type of multinodularity
A/C 17/30 18/20 NS
AST = aspartate aminotransferase; ALT = alanine aminotransferase; HBsAg = hepatitis B surface antigen; HCVAb = hepatitis C virus
antibody; AFP = a-fetoprotein.
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Figure 3. Comparison of cumulative survival curves be-
tween hepatectomy () and nonsurgical () groups, with
tumor number ≤ 3, largest tumor size ≤ 5 cm, serum 
albumin > 3.0 g/dL and serum total bilirubin < 2.0 mg/dL
(p = 0.0327).
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Figure 4. Cumulative survival rate was significantly better
in the hepatectomy group with one-block resection () than
in the hepatectomy group with multiple-site resection ()
and in the nonsurgical group () (p = 0.006) for patients
with tumor number ≤ 3, largest tumor size ≤ 5 cm, serum
albumin > 3.0 g/dL and serum total bilirubin < 2.0 mg/dL.
is significantly shorter than survival of patients
with single HCC. However, some still perform
aggressive surgical intervention and try to estab-
lish selection criteria for those patients who would
benefit from hepatectomy.
This issue has been addressed by dividing
multiple HCCs into primary tumors with intra-
hepatic metastasis (IM) and synchronous multi-
centric tumors, and advocating that synchronous
multicentric HCCs often affect multiple segments
of the liver and respond relatively well to partial
hepatectomy.18 However, the definition must rely
on a meticulous histopathologic examination or
genetic diagnosis by microsatellite loss of het-
erozygosity in the resected liver tumors.19,20 In
fact, by clonal analysis using Southern blot hy-
bridization, Hsu et al found unicentric origin IM
in 15 of 16 (93.8%) patients with multiple HCCs
that were histologically regarded as multicentric
in origin.21 Furthermore, they identified 18 of 99
patients with multiple HCCs, and only 11 pa-
tients had undergone multiple-site resection.18
This means that most of the patients with multi-
ple HCCs may be regarded as having IM, and
multicentric HCCs with synchronous occurrence
are thought to be clinically less important than
those with metachronous occurrence.22
In the present study, we demonstrated that
patients with tumor number ≤ 3 and largest tumor
size ≤ 5 cm had a better outcome if they initially
received hepatectomy than if they underwent
nonsurgical multidisciplinary therapy. The Liver
Cancer Study Group of Japan, which enrolled
12,888 patients with small-sized HCCs from a
nationwide survey of approximately 800 institutes
in Japan from 1988 to 1996, reported that pa-
tients in clinical stage II with two tumors > 2 cm
had higher survival rates following hepatic resec-
tion compared with the nonsurgical group.23 The
non-randomized and retrospective nature of both
studies may limit interpretation of the results.
Nevertheless, hepatectomy usually needs an ade-
quate surgical margin so that invisible micro-
metastasis, which is often at a distance from the
main tumor, may be removed and the frequency
of IM reduced.24,25
The indications for surgical and nonsurgical
modalities remain unclear for MNHCC. To iden-
tify which subgroup of patients would benefit the
most from surgery, we investigated all the patients
who underwent hepatectomy for MNHCC. We
found that those with serum AFP > 400 ng/mL, > 3
tumors, tumors with microvascular invasion or tu-
mor size > 5 cm, and those receiving multiple-site
hepatic resection had significantly poorer outcome
by univariate analysis. Because method and extent
of liver resection for the same patient may have
varied between different surgeons in the present
study, we also investigated the distribution and
location of the tumors and categorized them into
four types of multinodularity, as depicted in
Figure 1. Those patients with type A tumors had
a significantly higher survival rate than those with
other types. By multivariate analysis, however, only
multiple-site hepatic resection was a significant,
independent unfavorable factor, which indicates
that patients with MNHCC may benefit from one-
block resection, irrespective of other prognostic
factors. We speculate that patients with multiple
nodules resulting from IM must have microinva-
sion among the tumor invading fronts. Lai et al
investigated 23 resected HCC tumor specimens
(1.7–18.1 cm in diameter) and reported that the
distance from the main tumor to the microsatellite
site ranged from 0.1 mm to 71 mm. They demon-
strated that the presence of a large HCC (≥ 5 cm),
multinodular lesions, macroscopic venous tumor
thrombus, liver invasion, and non-encapsulated
dominant nodules were associated positively with
distance from the microsatellite to the main HCC
tumor.26 One-block resection may provide an op-
portunity for eradicating the tumor cells among
the tumor fronts, and thus improve patient sur-
vival. In the present study, the 5-year overall sur-
vival rate of patients who underwent one-block
resection for MNHCC was 35%. For patients with
total tumor number ≤ 3 and largest tumor size ≤
5 cm, those who underwent one-block resection
had favorable survival when compared with the
nonsurgical group (45.1% and 22.6%, respec-
tively). In contrast, those patients who underwent
multiple-site resection had no survival benefit.
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One drawback of the present study is that both
the surgical and nonsurgical groups were specially
selected and may have introduced some bias to
the analysis. Furthermore, small satellites are not
easy to confirm by imaging, and the nonsurgical
group may have had more advanced disease than
the hepatectomy group. However, the comparison
was made among those with tumor size ≤ 5 cm
and tumor number ≤ 3, which were also the se-
lection criteria for liver transplantation.13 The 
results of the present study may help us to select
treatment modalities for patients who are still on
the waiting list. When the tumor size reaches
5 cm or the tumor number increases, the large
majority of HCCs will demonstrate microscopic
invasion into portal venules or the lymphatics
that surround the periphery of the tumor. Liver
transplantation is relatively contraindicated.27
Our results indicate that one-block surgery may
provide the best treatment option for such 
advanced disease.
In conclusion, this study is in line with the re-
port of Ng et al, in which patients with MNHCC
benefited from hepatectomy.28 Although we de-
monstrated that the outcome of hepatectomy for
those with tumor number ≤ 3 and tumor size ≤
5 cm was superior to that in the nonsurgical group,
our analysis also showed that the best survival
was achieved with one-block hepatic resection,
regardless of tumor number or size. We recom-
mend that hepatectomy should be included in
the multidisciplinary therapy for MNHCC, pro-
vided that the liver function reserve is acceptable
for resection.
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